On May 20, we mark Global Clinical Trials Day, a moment to recognize the people, partnerships, and processes that make medical progress possible.
The date traces back to James Lind’s 1747 scurvy experiment aboard HMS Salisbury, often described as one of the earliest controlled clinical trials.[1] Nearly three centuries later, clinical research has evolved dramatically. Today, it is more global, more data-driven, more scientifically advanced, and more tightly regulated than ever before. But the core purpose remains unchanged: generating better evidence to improve patient care.
That evidence does not appear overnight. It is built carefully, one study, one site, one participant, and one data point at a time.
Why Clinical Trials Matter
Clinical trials are at the heart of modern medicine. They help determine whether a treatment is safe, effective, and meaningful for patients. They transform scientific discoveries into evidence that clinicians, regulators, and families can rely on when making important healthcare decisions.
The scale of this work is enormous. As of May 19, 2026, ClinicalTrials.gov listed more than 585,000 registered studies worldwide, including over 65,000 actively recruiting studies. Around two-thirds of recruiting studies listed locations outside the United States only, highlighting how global clinical development has become.[2]
And that global reach matters because clinical research is ultimately about people.
For someone living with cancer, a rare disease, or a chronic condition with limited treatment options, clinical trials can represent hope, time, and the possibility of a better future. At the same time, hope is not enough. Clinical research has to be rigorous. It has to be ethical, transparent, and carefully designed. Without strong evidence, medicine risks being guided by assumption, incomplete data, or treatments that have not been properly tested. That is why the World Health Organization describes trial registration as a scientific, ethical, and moral responsibility.[3]
But anyone who works in clinical research knows that trials are difficult to deliver.
Recruitment and retention remain major hurdles across the industry. A recent review published in the European Journal of Cardiovascular Nursing found that only around 50% of clinical research studies successfully recruit their intended sample size.[4] Site-level data show similar pressures. In WCG’s 2024 Clinical Research Site Challenges Report, 36% of sites identified recruitment and retention as a top challenge, while 35% cited study start-up as a major concern.[5]
These are not just operational challenges. Delays in recruitment or participant retention can slow timelines, increase costs, and limit the strength of the evidence generated. For patients waiting for new therapies, every delay matters.
Modern trials are also becoming more complex. Precision medicine, biomarker testing, oncology combination studies, adaptive trial designs, decentralized elements, and long-term follow-up are helping make research more targeted and personalized. But they also make execution more demanding.
That is where experience, partnership, and practical problem-solving become critical.
The People Behind Every Study
At Caidya, clinical development is about helping biopharma innovators navigate complex trials, reach patients globally, and generate high-quality data to support better decision-making.
Behind every study are teams working across countries, time zones, therapeutic areas, regulations, and patient communities to help move research forward responsibly.
Because while protocols define a study, people make it work.
Investigators and site teams explain studies to patients and answer difficult questions. Coordinators help participants navigate visits and procedures. Project leaders, monitors, data managers, statisticians, medical monitors, regulatory specialists, pharmacovigilance teams, and technology experts all contribute to protecting the quality and integrity of the research.
And at the center of it all are patients and caregivers.
Every participant makes a decision that deserves respect. They give their time, trust, and energy, often during already difficult circumstances. Some may benefit directly from participation, while others may not. But every contribution helps build knowledge that may improve care for future patients.
Building More Inclusive Clinical Trials
Global Clinical Trials Day is also an important reminder to ask: who is the evidence for?
For clinical research to truly serve patients, trials need to reflect the populations that may ultimately use the treatment. When women, older adults, ethnic minority groups, people with disabilities, rural communities, or other underserved populations are underrepresented, the evidence can become less complete and existing healthcare gaps may widen.[6]
Regulators are paying closer attention to this. The FDA’s June 2024 draft guidance on Diversity Action Plans reflects growing expectations around improving enrolment strategies and representation in clinical studies.[7] But guidance alone is not enough. More representative research depends on trust, accessible participation models, thoughtful study design, culturally aware communication, and reducing unnecessary burden for patients and caregivers.
A trial that is easier to participate in is not simply more convenient; it can also be more representative and more effective. Flexible visits, local laboratories, travel support, digital tools, decentralized trial components, and clearer communication can all help improve participation. But innovation must be implemented thoughtfully. New technologies should remove barriers, not create new ones.[8]
Looking Ahead
The best clinical research is both scientifically rigorous and deeply human.
It is built on strong methodology, ethical conduct, reliable data, and respect for real lives. Patient experience and data quality are not separate goals, they are closely connected. When participants feel informed, supported, and respected, studies are more likely to retain them and generate meaningful evidence.
On Global Clinical Trials Day, we celebrate the history of clinical research while recognizing the work still ahead. The future of clinical trials must continue to become more inclusive, more patient-centered, more transparent, and more responsive to the realities faced by sites, researchers, and communities worldwide.
At Caidya, we are proud to be part of that future.
Much of this work happens quietly behind the scenes, but its impact is significant. Every trial begins with a question. Every participant brings trust. Every study depends on people committed to getting the details right.
And every well-conducted clinical trial brings us one step closer to better care.
References
References were added to support the published data points and external claims.
[1] U.S. Food and Drug Administration. Clinical Trials Day. https://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/clinical-trials-day
[2] ClinicalTrials.gov. Trends, Charts, and Maps: Registered Studies and Recruiting Studies. Figures as of May 19, 2026. https://clinicaltrials.gov/about-site/trends-charts
[3] World Health Organization. International Standards for Clinical Trial Registries, 2018. https://www.who.int/publications/i/item/international-standards-for-clinical-trial-registers
[4] European Journal of Cardiovascular Nursing. Challenges and strategies for effective recruitment and retention of research participants, 2024. https://academic.oup.com/eurjcn/article/24/5/808/7935389
[5] WCG. 2024 Clinical Research Site Challenges Report, 2024. https://www.wcgclinical.com/wp-content/uploads/2024/10/WCG_2024_Clinical_Research_Site_Challenges_Report.pdf
[6] BMJ Medicine. Fostering diversity in clinical trials: need for evidence and action, 2024. https://bmjmedicine.bmj.com/content/3/1/e000984
[7] U.S. Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies, draft guidance, June 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies
[8] Nature Medicine. Recommendations to promote equity, diversity and inclusion in decentralized clinical trials, 2024. https://www.nature.com/articles/s41591-024-03323-w